Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.74 |
| ▸ | CA12 | O43570 | 1/20 | 0.68 |
| ▸ | CA1 | P00915 | 1/20 | 0.68 |
| ▸ | CA2 | P00918 | 1/20 | 0.68 |
| ▸ | CA9 | Q16790 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | ELAVL1 | Q15717 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 3/20 | 0.53 |
| ▸ | HTR7 | P34969 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28984412 | 0.91 | L3MBTL1 (0.77) | HTR6CA12CA1CA2CA9 | |
| SCHEMBL19737472 | 0.87 | HTR6 (0.66) | HTR6L3MBTL1HTR2AHTR7DRD2 | |
| SCHEMBL19737552 | 0.87 | HTR6 (0.55) | HTR6CA12CA1CA2CA9 | |
| SCHEMBL3644542 | 0.86 | HTR6 (1.00) | HTR6CA12CA1CA2CA9 | |
| Dimethylamine SCHEMBL21222407 | 0.84 | HTR6 (0.65) | HTR6L3MBTL1HTR2AHTR7DRD2 | |
| SCHEMBL4338217 | 0.84 | HTR6 (0.65) | HTR6CA12CA1CA2CA9 | |
| SCHEMBL19737624 | 0.82 | HTR6 (0.63) | HTR6HTR2AHTR7DRD2 | |
| SCHEMBL3044328 | 0.82 | ELAVL1 (0.51) | HTR6CA12CA1CA2CA9 | |
| SCHEMBL7497252 | 0.82 | HTR6 (0.74) | HTR6CA12CA1CA2CA9 | |
| SCHEMBL13302272 | 0.80 | HTR6 (0.62) | HTR6L3MBTL1HTR2AHTR7DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2486010-B1 | ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2019-06-12 | — | — | EP | disclosed |
| EP-2486010-B1 | ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2019-06-12 | — | — | EP | disclosed |
| US-8710243-B2 | Estrogen receptor ligands | KARO BIO AB (SE) | 2014-04-29 | — | — | US | disclosed |
| EP-2486010-A2 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2012-08-15 | — | — | EP | disclosed |
| US-20120202861-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2012-08-09 | — | — | US | disclosed |
| US-20120202861-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2012-08-09 | — | — | US | disclosed |
| US-20120202861-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2012-08-09 | — | — | US | disclosed |
| WO-2011042473-A2 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011042473-A2 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-04-14 | — | — | WO | disclosed |
| US-7411082-B2 | Synthesizing method for compound, and catalyst for synthesis reaction | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. (GB) | 2008-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202861-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR1, ESRRA, GPER1 | HTR6 951/4885CA12 2226/4885CA1 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.